Business
Arecor's Polysaccharide Vaccine Patent Upheld
Arecor's Polysaccharide Vaccine Patent Upheld.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6478O\n Arecor Therapeutics PLC\n 11 October 2021\n \n \n \n \n Arecor Therapeutics plc\n \n \n (\"Arecor\", the \"Company\" or the \"Group\")\n \n \n \n \n \n ARECOR'S POLYSACCHARIDE VACCINE PATENT UPHELD\n \n \n \n \n \n \n Cambridge, UK, \n \n 11 October 2021:\n Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, \n continues to build a strong patent portfolio protecting its\n proprietary \n Arestat™ technology. Arecor is pleased to announce that its European patent EP2457590 on polysaccharide vaccines has been successfully upheld following opposition appeal proceedings filed by GlaxoSmithKline Biologicals SA (GSK) at the Boards of Appeal of the European Patent Office.\n \n \n \n \n \n As part of the Intellectual Property legislation in Europe, patents can be opposed by other companies, within a certain period of time following their formal grant. The opposition process can result in the patent being revoked, amended or upheld in its original form. In accordance with this process, at an oral hearing on 1 October 2021, the Boards of Appeal, which is the final judicial instance in the procedures, considered an appeal filed by GSK in response to an earlier ruling in Arecor's favour and decided to dismiss the appeal, upholding the patent as granted.\n \n \n \n \n \n Arecor's European patent EP2457590 protects novel compositions of a specific type of vaccines, called polysaccharide vaccines. Examples of polysaccharide vaccines are vaccines that are used to protect against Meningitis or Pneumonia. Such products are known to degrade over time, leading to gradual loss of potency. Arecor's novel compositions protected by this patent, prevent such degradation and enable the development of improved polysaccharide vaccines. This includes more convenient dosage forms that can be used outside the cold chain, thereby increasing the efficiency of immunisation coverage. \n \n \n \n \n \n Arecor has invested in building a strong patent portfolio to protect the \n Arestat™ technology platform. The Group's intellectual property portfolio currently comprises 33 patent families, including >50 granted patents in Europe in the US and in other key territories. \n \n \n \n \n \n A...